REG - Oxford Biomedica PLC - Total Voting Rights

Oxford BioMedicaAnnouncement

01/03/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240301:nRSA0544Fa&default-theme=true

RNS Number : 0544F  Oxford Biomedica PLC  01 March 2024

Oxford Biomedica

Total Voting Rights

 

 

Oxford, UK - 01 March 2024: Oxford Biomedica plc (LSE:OXB) ("Oxford
Biomedica" or "the Company"), a quality and innovation-led cell and gene
therapy CDMO, today announces that in accordance with the FCA's Disclosure
Guidance and Transparency Rule 5.6.1R, the Company's issued share capital as
at the close of business on 29 February 2024 consisted of 99,957,395 ordinary
shares of 50 pence each ("Ordinary Shares"). There are no Ordinary Shares held
in treasury.

 

Accordingly, the total number of voting rights in Oxford Biomedica at the date
of this notice is 99,957,395.

 

The above figure (99,957,395) may be used by shareholders as the denominator
for the calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, Oxford Biomedica
under the FCA's Disclosure Guidance and Transparency Rules.

 

-Ends-

 

 For further information, please contact:

 Oxford Biomedica plc:                     Tel: +44 (0)1865 783 000

 Natalie Walter, Company Secretary

 

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene
therapy CDMO with a mission to enable its clients to deliver life changing
therapies to patients around the world.

 

One of the original pioneers in cell and gene therapy, the Company has more
than 25 years of experience in viral vectors; the driving force behind the
majority of gene therapies. The Company collaborates with some of the world's
most innovative pharmaceutical and biotechnology companies, providing viral
vector development and manufacturing expertise in lentivirus, adeno-associated
virus (AAV), adenoviral vectors, and other viral vector types. Oxford
Biomedica's world-class capabilities span from early-stage development to
commercialisation. These capabilities are supported by robust
quality-assurance systems, analytical methods and depth of regulatory
expertise.

 

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It
has locations across Oxfordshire, UK, Lyon and Strasbourg, France, and near
Boston, MA, US. Learn more at www.oxb.com (https://www.oxb.com/) , and follow
us on LinkedIn (https://www.linkedin.com/company/oxford-biomedica/) and
YouTube (https://www.youtube.com/user/OxfordBioMedica) .

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVREAXANALPLEFA